STORYLINE: An IVD manufacturer identifies through its post-market surveillance (PMS) activities an increasing complaint trend related to incorrect setup or use of an IVD. The manufacturer evaluates the trend and determines that insufficient or potentially unclear information in the labelling may contribute to the observed use error. The manufacturer updates the risk analysis and determines that the IFU should be revised to provide clearer setup instructions and/or warnings. Following the manufacturer’s change-control process, the revised IFU is approved and the corresponding electronic labelling information is updated. Where necessary, affected customers are informed of the updated safety information. During conformity assessment or surveillance activities, the Notified Body assesses whether information obtained through PMS has been effectively linked to risk management, CAPA, labelling changes and user communication.
PRIMARY PERSONA AND SUPPORTING PERSONAS WHERE RELEVANT:
Primary persona: Notified Body product reviewer.
Supporting personas: Manufacturer PMS/vigilance representative; regulatory affairs representative; quality/CAPA representative; risk-management specialist; labelling/technical documentation representative; customer communication representative; and, where relevant, IVD users such as laboratory personnel or healthcare professionals.
INFORMATION RECORDS: The assessor needs evidence demonstrating that the manufacturer has a systematic process for translating relevant post-market information into appropriate risk-control and labelling actions. Evidence reviewed includes: PMS reports and trend analyses, Complaint records, CAPA records, Updated Risk Management File, Previous and revised IFU/label versions, Change-control documentation, e-label update/approval records, Customer notification records
ROUTE(S) OF ACCESS TO INFORMATION:
Today: PMS and complaint information is collected and evaluated within the manufacturer’s quality management and PMS systems. Once a labelling change is approved, the revised IFU is introduced through the applicable document-control process and the e-label/digital information source is updated. Customers may receive information through established communication channels where required.
Target: A controlled and traceable process linking PMS signals to risk management, labelling updates, user communication, and effectiveness monitoring.
TRUSTWORTHINESS/QUALITY CONSIDERATIONS: The manufacturer should ensure that the revised information is approved, accurate, consistent with the current risk assessment and associated with the correct IVD and applicable version. The digital labelling platform should prevent obsolete information from being presented as current while maintaining appropriate traceability of historical versions. The manufacturer should be able to demonstrate when the revised information became effective and, where user communication was necessary, which affected users/customers were targeted. The effectiveness of the change should subsequently be monitored through PMS to determine whether the identified setup/use issue has been adequately addressed.
PRELIMINARY KPI CONSIDERATIONS:
Availability and retrievability of previous IFU versions
Number of Notified Body findings concerning PMS-to-labelling linkage or change control
Traceability between PMS signal, risk-management action, CAPA and labelling change
Recurrence rate of the identified use error after implementation
Percentage of identified affected customers successfully notified, where notification is required